VEL-101 to Prevent Rejection After Kidney Transplantation
This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.
Greater than or equal to 18 years of age [+7]
Negative for EBV or Epstein-Barr nuclear antigen antibody [+23]